Evidence map›Paper›PMID 41701690›Full record

ArticlePloS one2026

Effectiveness and acceptability of the unified protocol for the transdiagnostic treatment of emotional disorders in people with long COVID-19: Study protocol for a randomized controlled trial.

Verónica Martínez-Borba, Andrés E Rodríguez-Márquez, Sara Garcés-Arilla, Óscar Peris-Baquero, María Vicenta Navarro-Haro, Esther Del Corral-Beamonte, Jorge Osma

Registry-linked trialAbstract readClinical Trial Protocol
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06928480 (Effectiveness and Acceptability of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in People With Long COVID-19.), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06928480 narecruitingnot on this map

Effectiveness and Acceptability of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in People With Long COVID-19.

TypeinterventionalSponsorInstituto de Investigación Sanitaria AragónRan2025 to 2026Enrolled90ConditionsLong Covid-19, Emotional Disorder, Anxiety, Depression DisordersArmsUnified Protocol for the Transdiagnostic Treatment of Emotional Disorders, Treatment as Usual (TAU)
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Verónica Martínez-BorbaDepartment of Psychology and Sociology, Faculty of Social and Human Sciences, Universidad de Zaragoza, Teruel, Spain.ORCID https://orcid.org/0000-0003-2082-8115
Andrés E Rodríguez-MárquezDepartment of Psychology and Sociology, Faculty of Social and Human Sciences, Universidad de Zaragoza, Teruel, Spain.
Sara Garcés-ArillaDepartment of Psychology and Sociology, Faculty of Social and Human Sciences, Universidad de Zaragoza, Teruel, Spain.
Óscar Peris-BaqueroDepartment of Psychology and Sociology, Faculty of Social and Human Sciences, Universidad de Zaragoza, Teruel, Spain.ORCID https://orcid.org/0000-0002-2437-1207
María Vicenta Navarro-HaroDepartment of Psychology and Sociology, Faculty of Social and Human Sciences, Universidad de Zaragoza, Teruel, Spain.
Esther Del Corral-BeamonteInternal Medicine, Hospital Royo Villanova, Zaragoza, Spain.
Jorge OsmaDepartment of Psychology and Sociology, Faculty of Social and Human Sciences, Universidad de Zaragoza, Teruel, Spain.ORCID https://orcid.org/0000-0002-7293-318X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLong COVID-19 is a medical condition associated with persistent physical, cognitive, and emotional symptoms. Despite its significant impact, there are still few psychological interventions-especially with transdiagnostic approaches- that have been rigorously tested in this population. The aim of the present protocol is to describe a randomized controlled trial to examine the effectiveness and acceptability of the online, group-delivered Unified Protocol (UP) for improving emotional, and cognitive outcomes in adults with long COVID-19. We expect greater improvements in emotional and cognitive outcomes for the UP group compared to controls. Additionally, exploratory analyses will assess changes in neurocognitive performance and hair cortisol/cortisone levels as potential correlates of treatment response.

methods90 individuals diagnosed with long COVID-19 will be randomized to an experimental group or a waiting-list control group (1:1 ratio). Participants in the experimental group will receive the UP across 12 online group sessions. Longitudinal assessments (pre-treatment, post-treatment and 3, 6 and 12 months follow-ups) will include psychological (e.g., anxiety and depressive symptoms) and cognitive outcomes (e.g., memory failures). Participants in the experimental group will also complete neuropsychological tests and will provide hair samples for the assessment of cortisol/cortisone levels. DATA ANALYSES: Baseline characteristics will be described using descriptive statistics, and linear mixed-effects models will evaluate the effects of time, group, and their interaction on psychological and cognitive outcomes. Neuropsychological performance and hair cortisol levels will be analyzed over time in the experimental group. Associations between cortisol and psychological or cognitive measures will be explored through correlational analyses.

conclusionsWe expect positive outcomes after the intervention in acceptability and in emotional symptoms and cognitive complaints in individuals living with long COVID-19, the maintenance of the benefits in all follow-ups, and statistically significant changes in favor of the UP condition in comparison with the waiting-list control group. If effective, the UP could provide an accessible and evidence-based psychological treatment for this population, improving the quality of healthcare to individuals with long COVID-19.

trial registrationclinicatrials.gov (registration identifier: NCT06928480; May 22, 2025).

Indexed as

COVID-19AdultAnxietyCognitionDepressionEmotionsFemaleHairHumansHydrocortisoneMaleNeuropsychological TestsPost-Acute COVID-19 SyndromeRandomized Controlled Trials as TopicSARS-CoV-2Treatment OutcomeHydrocortisone

Identifiers

PMID41701690
PMCPMC12912558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.